{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:43:43Z","timestamp":1750700623008},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00210-023-02891-x","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:02:33Z","timestamp":1702972953000},"page":"4461-4470","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs"],"prefix":"10.1007","volume":"397","author":[{"given":"Jaka","family":"Fadraersada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Alva-Gallegos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Sko\u0159epa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franti\u0161ek","family":"Musil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Javorsk\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Matou\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka Kujovsk\u00e1","family":"Kr\u010dmov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark\u00e9ta","family":"Pacl\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Carazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladim\u00edr","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u0159emysl","family":"Mlad\u011bnka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"3","key":"2891_CR1","doi-asserted-by":"publisher","first-page":"204s","DOI":"10.1378\/chest.126.3_suppl.204S","volume":"126","author":"J Ansell","year":"2004","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists. Chest 126(3):204s\u2013233s. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.204S","journal-title":"Chest"},{"key":"2891_CR2","doi-asserted-by":"publisher","unstructured":"Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. https:\/\/doi.org\/10.1111\/jth.12149","DOI":"10.1111\/jth.12149"},{"issue":"3","key":"2891_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11892-007-0035-1","volume":"7","author":"G Boden","year":"2007","unstructured":"Boden G, Rao AK (2007) Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 7(3):223\u2013227. https:\/\/doi.org\/10.1007\/s11892-007-0035-1","journal-title":"Curr Diab Rep"},{"issue":"18","key":"2891_CR4","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMra1011670","volume":"364","author":"JI Borissoff","year":"2011","unstructured":"Borissoff JI, Spronk HMH, ten Cate H (2011) Mechanisms of disease the hemostatic system as a modulator of atherosclerosis. N Engl J Med 364(18):1746\u20131760. https:\/\/doi.org\/10.1056\/NEJMra1011670","journal-title":"N Engl J Med"},{"key":"2891_CR5","doi-asserted-by":"publisher","unstructured":"Carazo A, Hrubsa M, Konecny L, Skorepa P, Paclikova M, Musil F et al (2022) Sex-related differences in platelet aggregation: a literature review supplemented with local data from a group of generally healthy individuals. Semin Thromb Hemost. https:\/\/doi.org\/10.1055\/s-0042-1756703","DOI":"10.1055\/s-0042-1756703"},{"key":"2891_CR6","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1111\/jth.12720","volume":"12","author":"BJ Dale","year":"2014","unstructured":"Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW (2014) Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various agents. J Thromb Haemost 12:1810\u20131815. https:\/\/doi.org\/10.1111\/jth.12720","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2891_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1160\/TH16-02-0087","volume":"116","author":"M Di Nisio","year":"2016","unstructured":"Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller K, Cohen AT et al (2016) Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies. Thromb Haemost 116(4):739\u2013746. https:\/\/doi.org\/10.1160\/TH16-02-0087","journal-title":"Thromb Haemost"},{"issue":"4","key":"2891_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11239-012-0758-y","volume":"34","author":"B Doepker","year":"2012","unstructured":"Doepker B, Mount KL, Ryder LJ, Gerlach AT, Murphy CV, Philips GS (2012) Bleeding risk factors associated with argatroban therapy in the critically ill. J Thromb Thrombolysis 34(4):491\u2013498. https:\/\/doi.org\/10.1007\/s11239-012-0758-y","journal-title":"J Thromb Thrombolysis"},{"key":"2891_CR9","doi-asserted-by":"publisher","first-page":"CD005134","DOI":"10.1002\/14651858.CD005134.pub3","volume":"10","author":"K Dong","year":"2016","unstructured":"Dong K, Song Y, Li X, Ding J, Gao Z, Lu D, Zhu Y (2016) Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database Syst Rev 10:CD005134. https:\/\/doi.org\/10.1002\/14651858.CD005134.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"2891_CR10","doi-asserted-by":"publisher","unstructured":"Dunois C (2021) Laboratory monitoring of direct oral anticoagulants (DOACs). Biomedicines 9(5). https:\/\/doi.org\/10.3390\/biomedicines9050445","DOI":"10.3390\/biomedicines9050445"},{"issue":"9","key":"2891_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.15537\/smj.2018.9.22630","volume":"39","author":"AM Elkhalifa","year":"2018","unstructured":"Elkhalifa AM (2018) Effects of cigarette smoking on coagulation screening tests and platelet counts in a Sudanese male adults population. Saudi Med J 39(9):897\u2013901. https:\/\/doi.org\/10.15537\/smj.2018.9.22630","journal-title":"Saudi Med J"},{"issue":"4","key":"2891_CR12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5114\/aoms.2016.58928","volume":"13","author":"MS Ellulu","year":"2017","unstructured":"Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y (2017) Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 13(4):851\u2013863. https:\/\/doi.org\/10.5114\/aoms.2016.58928","journal-title":"Arch Med Sci"},{"issue":"1","key":"2891_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","volume":"48","author":"BI Eriksson","year":"2009","unstructured":"Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 48(1):1\u201322. https:\/\/doi.org\/10.2165\/0003088-200948010-00001","journal-title":"Clin Pharmacokinet"},{"key":"2891_CR14","doi-asserted-by":"publisher","first-page":"107424842110546","DOI":"10.1177\/10742484211054609","volume":"27","author":"E Ferroni","year":"2022","unstructured":"Ferroni E, Denas G, Gennaro N, Fedeli U, Pengo V (2022) Gender related differences in gastrointestinal bleeding with oral anticoagulation in atrial fibrillation. J Cardiovasc Pharmacol Ther 27:10742484211054609. https:\/\/doi.org\/10.1177\/10742484211054609","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"7","key":"2891_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.7326\/M19-2522","volume":"172","author":"M Fralick","year":"2020","unstructured":"Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ (2020) Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med 172(7):463\u2013473. https:\/\/doi.org\/10.7326\/M19-2522","journal-title":"Ann Intern Med"},{"issue":"1","key":"2891_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0192623310389474","volume":"39","author":"AJ Gale","year":"2011","unstructured":"Gale AJ (2011) Continuing education course #2: current understanding of hemostasis. Toxicol Pathol 39(1):273\u2013280. https:\/\/doi.org\/10.1177\/0192623310389474","journal-title":"Toxicol Pathol"},{"issue":"20","key":"2891_CR17","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","volume":"290","author":"AS Go","year":"2003","unstructured":"Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM et al (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290(20):2685\u20132692. https:\/\/doi.org\/10.1001\/jama.290.20.2685","journal-title":"JAMA"},{"key":"2891_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/JBM.S38762","volume":"5","author":"E Grouzi","year":"2014","unstructured":"Grouzi E (2014) Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. J Blood Med 5:131\u2013141. https:\/\/doi.org\/10.2147\/JBM.S38762","journal-title":"J Blood Med"},{"issue":"13","key":"2891_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","volume":"123","author":"GJ Hankey","year":"2011","unstructured":"Hankey GJ, Eikelboom JW (2011) Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 123(13):1436\u20131450. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.004424","journal-title":"Circulation"},{"issue":"6","key":"2891_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/FJC.0b013e3181926928","volume":"52","author":"MJ Hursting","year":"2008","unstructured":"Hursting MJ, Verme-Gibboney CN (2008) Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol 52(6):561\u2013566. https:\/\/doi.org\/10.1097\/FJC.0b013e3181926928","journal-title":"J Cardiovasc Pharmacol"},{"issue":"13","key":"2891_CR21","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA (2020) Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 9(13):e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2891_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1160\/TH15-11-0847","volume":"115","author":"C Keyl","year":"2016","unstructured":"Keyl C, Zimmer E, Bek MJ, Wiessner M, Trenk D (2016) Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia. Thromb Haemost 115(6):1081\u20131089. https:\/\/doi.org\/10.1160\/TH15-11-0847","journal-title":"Thromb Haemost"},{"issue":"1","key":"2891_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3343\/alm.2015.35.1.15","volume":"35","author":"JA Kim","year":"2015","unstructured":"Kim JA, Kim JE, Song SH, Kim HK (2015) Influence of blood lipids on global coagulation test results. Ann Lab Med 35(1):15\u201321. https:\/\/doi.org\/10.3343\/alm.2015.35.1.15","journal-title":"Ann Lab Med"},{"issue":"7","key":"2891_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.numecd.2020.03.015","volume":"30","author":"M Kim","year":"2020","unstructured":"Kim M, Yoo HJ, Lee D, Lee JH (2020) Oxidized LDL induces procoagulant profiles by increasing lysophosphatidylcholine levels, lysophosphatidylethanolamine levels, and Lp-PLA2 activity in borderline hypercholesterolemia. Nutr Metab Cardiovasc Dis 30(7):1137\u20131146. https:\/\/doi.org\/10.1016\/j.numecd.2020.03.015","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"2891_CR25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.talanta.2011.06.027","volume":"85","author":"L Krcmova","year":"2011","unstructured":"Krcmova L, Solichova D, Melichar B, Kasparova M, Plisek J, Sobotka L, Solich P (2011) Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throuput HPLC. Talanta 85(3):1466\u20131471. https:\/\/doi.org\/10.1016\/j.talanta.2011.06.027","journal-title":"Talanta"},{"issue":"2","key":"2891_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47(2):218\u2013226. https:\/\/doi.org\/10.1177\/0091270006296058","journal-title":"J Clin Pharmacol"},{"key":"2891_CR27","doi-asserted-by":"crossref","unstructured":"Levi M (2017) Inflammation and Coagulation. In: In: Cavaillon J, Singer M (ed) Inflammation from molecular and cellular mechanisms to the clinic. Wiley, Weinheim (pp. 833-860)","DOI":"10.1002\/9783527692156.ch32"},{"issue":"3","key":"2891_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cll.2014.06.005","volume":"34","author":"JH Levy","year":"2014","unstructured":"Levy JH, Szlam F, Wolberg AS, Winkler A (2014) Clinical use of the activated partial thromboplastin time and prothrombin time for screening a review of the literature and current guidelines for testing. Clin Lab Med 34(3):453\u2013477. https:\/\/doi.org\/10.1016\/j.cll.2014.06.005","journal-title":"Clin Lab Med"},{"issue":"14","key":"2891_CR29","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/01.cir.103.14.1838","volume":"103","author":"BE Lewis","year":"2001","unstructured":"Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM et al (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103(14):1838\u20131843. https:\/\/doi.org\/10.1161\/01.cir.103.14.1838","journal-title":"Circulation"},{"key":"2891_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fmed.2020.00280","volume":"7","author":"G Li","year":"2020","unstructured":"Li G, Zeng J, Zhang J, Thabane L (2020) Comparative effects between direct oral anticoagulants for acute venous thromboembolism: indirect comparison from randomized controlled trials. Front Med (Lausanne) 7:280. https:\/\/doi.org\/10.3389\/fmed.2020.00280","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"2891_CR31","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","volume":"9","author":"KH Liesenfeld","year":"2011","unstructured":"Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD et al (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9(11):2168\u20132175. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04498.x","journal-title":"J Thromb Haemost"},{"issue":"1-2","key":"2891_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clinbiochem.2008.10.01","volume":"42","author":"G Lippi","year":"2009","unstructured":"Lippi G, Franchini M, Targher G, Montagnana M, Salvagno GL, Guidi GC, Favaloro EJ (2009) Epidemiological association between fasting plasma glucose and shortened APTT. Clin Biochem 42(1-2):118\u2013120. https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.10.01","journal-title":"Clin Biochem"},{"issue":"2","key":"2891_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1467-789x.2002.00056.x","volume":"3","author":"I Mertens","year":"2002","unstructured":"Mertens I, Van Gaal LF (2002) Obesity, haemostasis and the fibrinolytic system. Obes Rev 3(2):85\u2013101. https:\/\/doi.org\/10.1046\/j.1467-789x.2002.00056.x","journal-title":"Obes Rev"},{"issue":"4","key":"2891_CR34","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/rth2.12146","volume":"2","author":"S Piran","year":"2018","unstructured":"Piran S, Traquair H, Chan N, Bhagirath V, Schulman S (2018) Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost 2(4):684\u2013688. https:\/\/doi.org\/10.1002\/rth2.12146","journal-title":"Res Pract Thromb Haemost"},{"key":"2891_CR35","doi-asserted-by":"publisher","first-page":"e7097","DOI":"10.1136\/bmj.e7097","volume":"345","author":"LH Rasmussen","year":"2012","unstructured":"Rasmussen LH, Larsen TB, Graungaard T, Skjoth F, Lip GY (2012) Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 345:e7097. https:\/\/doi.org\/10.1136\/bmj.e7097","journal-title":"BMJ"},{"issue":"15","key":"2891_CR36","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa035029","volume":"348","author":"PM Ridker","year":"2003","unstructured":"Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR et al (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425\u20131434. https:\/\/doi.org\/10.1056\/NEJMoa035029","journal-title":"N Engl J Med"},{"issue":"4","key":"2891_CR37","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1160\/th03-01-0014","volume":"91","author":"GA Rosito","year":"2004","unstructured":"Rosito GA, D\u2019Agostino RB, Massaro J, Lipinska L, Mittleman MA, Sutherland P et al (2004) Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91(4):683\u2013689. https:\/\/doi.org\/10.1160\/th03-01-0014","journal-title":"Thromb Haemost"},{"key":"2891_CR38","doi-asserted-by":"publisher","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment. Chest 133(6):257s-298s. https:\/\/doi.org\/10.1378\/chest.08-0674","DOI":"10.1378\/chest.08-0674"},{"issue":"3","key":"2891_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","volume":"20","author":"SK Swan","year":"2000","unstructured":"Swan SK, Hursting MJ (2000) The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20(3):318\u2013329. https:\/\/doi.org\/10.1592\/phco.20.4.318.34881","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2891_CR40","doi-asserted-by":"publisher","first-page":"e18729","DOI":"10.1097\/MD.0000000000018729","volume":"99","author":"E Tao","year":"2020","unstructured":"Tao E, Luo YL, Tao Z, Wan L (2020) A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin. Medicine (Baltimore) 99(3):e18729. https:\/\/doi.org\/10.1097\/MD.0000000000018729","journal-title":"Medicine (Baltimore)"},{"key":"2891_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijcard.2018.03.060","volume":"262","author":"L Tittl","year":"2018","unstructured":"Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J (2018) Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol 262:85\u201391. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.060","journal-title":"Int J Cardiol"},{"key":"2891_CR42","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1538-7836.2010.04106.x","volume":"9","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: result of an in vitro study. J Thromb Haemost 9:226\u2013228. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.04106.x","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2891_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/bcpt.13492","volume":"128","author":"P Tveden-Nyborg","year":"2021","unstructured":"Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J (2021) BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol 128(1):4\u20138. https:\/\/doi.org\/10.1111\/bcpt.13492","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"2891_CR44","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/jth.14573","volume":"17","author":"FA van der Toorn","year":"2019","unstructured":"van der Toorn FA, de Mutsert R, Lijfering WM, Rosendaal FR, Vlieg AV (2019) Glucose metabolism affects coagulation factors: The NEO study. J Thromb Haemost 17(11):1886\u20131897. https:\/\/doi.org\/10.1111\/jth.14573","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2891_CR45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/labmed\/lmx050","volume":"48","author":"WE Winter","year":"2017","unstructured":"Winter WE, Flax SD, Harris NS (2017) Coagulation testing in the core laboratory. Lab Med 48(4):295\u2013313. https:\/\/doi.org\/10.1093\/labmed\/lmx050","journal-title":"Lab Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02891-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T08:27:09Z","timestamp":1716366429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02891-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2891"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02891-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the University Hospital in Hradec Kr\u00e1lov\u00e9 (No. 202007 S01P from June 18, 2020). All experiments conformed to the latest declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All donors gave their consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}